Pacific Biosciences of California Inc (PACB)

5.28
0.11 2.00
NASDAQ : Health Care
Prev Close 5.39
Open 5.33
Day Low/High 5.22 / 5.33
52 Wk Low/High 3.58 / 14.00
Volume 537.85K
Avg Volume 1.01M
Exchange NASDAQ
Shares Outstanding 115.59M
Market Cap 628.82M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

PacBio Announces New Agreement With Novogene To Purchase Ten Sequel Systems

PacBio Announces New Agreement With Novogene To Purchase Ten Sequel Systems

Increases Novogene's Capacity to Run 20 Sequel Systems at a Time

PacBio Technology Resolves Complex Maize Genome, Driving Demand For Other Large-Scale AgBio Sequencing Projects

SMRT Sequencing Offers Significant Improvements for Reference Genomes at Much Lower Cost

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering

Biotech Movers: Pacific Biosciences Shares Lower After Pricing Stock Offering

Pacific Biosciences of California, AveXis and Novavax were among the biotech stock movers in premarket trading on Thursday.

Recent Publications Demonstrate Rapid Adoption Of SMRT Sequencing For Plant And Animal Transcriptome Analysis

Long Reads Reveal Important Genes and Splicing Complexity Missed by Short-Read Sequencers

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Pacific Biosciences Of California, Inc. Announces First Quarter 2017 Financial Results

Product and Service Revenue Increases by 60% Over Same Period in Previous Year

Short Interest Makes 14.2% Move For PACB

The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 1,825,018 share increase in total short interest for Pacific Biosciences of California Inc , to 14,717,375, an increase of 14.16% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics

Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics

Pacific Biosciences of California, AMAG Pharmaceuticals and Global Blood Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Pacific Biosciences Announces Fourth Quarter 2016 Financial Results

Product and Service Revenue Increases by 92% Over Same Period in Previous Year

More Than 115 Presentations And Posters Feature PacBio SMRT Sequencing To Decipher Complex Plant And Animal Genomes At Annual PAG Conference

More Than 115 Presentations And Posters Feature PacBio SMRT Sequencing To Decipher Complex Plant And Animal Genomes At Annual PAG Conference

Over 60 new plant and animal genomes assembled with PacBio data will be presented

Short Interest In Pacific Biosciences Of California Moves 13.4% Lower

Short Interest In Pacific Biosciences Of California Moves 13.4% Lower

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 2,487,057 share decrease in total short interest for Pacific Biosciences of California Inc , to 16,118,732, a decrease of 13.37% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

UPDATE -- Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

UPDATE -- Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

Structural Variant Detection, De Novo Assembly and Targeted Sequencing Applications Improved

Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

Pacific Biosciences Improves Key Applications On The Sequel System With New Chemistry And Software Release

Structural Variant Detection, De Novo Assembly and Targeted Sequencing Applications Improved

Health Sector Down As Report of Industry Price Collusion Surfaces

Health Sector Down As Report of Industry Price Collusion Surfaces

The healthcare sector was dragged down by reports of price collusion and worse-than-expected third-quarter profits.

Pacific Biosciences of California Enters Oversold Territory (PACB)

Pacific Biosciences of California Enters Oversold Territory (PACB)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Pacific Biosciences Of California, Inc. Announces Third Quarter 2016 Financial Results

Pacific Biosciences Of California, Inc. Announces Third Quarter 2016 Financial Results

Revenue Increases by 80% Over Same Period in Previous Year

PacBio Files ITC Patent Infringement Complaint Against Oxford Nanopore

PacBio Files ITC Patent Infringement Complaint Against Oxford Nanopore

Action Seeks ITC Investigation and Exclusion Order Against Infringing Single-Molecule Sequencing Products

First Week of June 2017 Options Trading For Pacific Biosciences of California (PACB)

First Week of June 2017 Options Trading For Pacific Biosciences of California (PACB)

Investors in Pacific Biosciences of California Inc saw new options begin trading this week, for the June 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TheStreet Quant Rating: D- (Sell)